Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 347 | nM | 17125260 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 3460 | nM | 17125260 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 291 | nM | 17125260 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 750 | nM | 17302398 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 2060 | nM | 20095577 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 10000 | nM | 20095577 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 800 | nM | 20095577 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC317639 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9121 | High Similarity | NPC73765 |
0.9121 | High Similarity | NPC283698 |
0.9011 | High Similarity | NPC36985 |
0.9011 | High Similarity | NPC17892 |
0.8791 | High Similarity | NPC320249 |
0.8791 | High Similarity | NPC322594 |
0.8681 | High Similarity | NPC324390 |
0.8602 | High Similarity | NPC324516 |
0.8602 | High Similarity | NPC318166 |
0.8587 | High Similarity | NPC327344 |
0.8242 | Intermediate Similarity | NPC89051 |
0.8242 | Intermediate Similarity | NPC43246 |
0.8218 | Intermediate Similarity | NPC329277 |
0.8152 | Intermediate Similarity | NPC163352 |
0.8152 | Intermediate Similarity | NPC210456 |
0.8058 | Intermediate Similarity | NPC149843 |
0.8058 | Intermediate Similarity | NPC155087 |
0.7912 | Intermediate Similarity | NPC106780 |
0.7826 | Intermediate Similarity | NPC71339 |
0.7826 | Intermediate Similarity | NPC112842 |
0.7604 | Intermediate Similarity | NPC315063 |
0.7553 | Intermediate Similarity | NPC325723 |
0.75 | Intermediate Similarity | NPC120887 |
0.7444 | Intermediate Similarity | NPC329077 |
0.7426 | Intermediate Similarity | NPC328779 |
0.7423 | Intermediate Similarity | NPC171116 |
0.74 | Intermediate Similarity | NPC226769 |
0.74 | Intermediate Similarity | NPC280946 |
0.74 | Intermediate Similarity | NPC6166 |
0.7282 | Intermediate Similarity | NPC328914 |
0.7157 | Intermediate Similarity | NPC90240 |
0.7129 | Intermediate Similarity | NPC329384 |
0.7034 | Intermediate Similarity | NPC284651 |
0.6809 | Remote Similarity | NPC325902 |
0.67 | Remote Similarity | NPC190334 |
0.67 | Remote Similarity | NPC62927 |
0.6634 | Remote Similarity | NPC328806 |
0.64 | Remote Similarity | NPC229249 |
0.6383 | Remote Similarity | NPC315806 |
0.6364 | Remote Similarity | NPC319753 |
0.6095 | Remote Similarity | NPC109188 |
0.6032 | Remote Similarity | NPC315058 |
0.6 | Remote Similarity | NPC325750 |
0.5966 | Remote Similarity | NPC478024 |
0.5891 | Remote Similarity | NPC313962 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC317639 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9121 | High Similarity | NPD9639 | Clinical (unspecified phase) |
0.8736 | High Similarity | NPD9546 | Phase 2 |
0.8242 | Intermediate Similarity | NPD9581 | Clinical (unspecified phase) |
0.8242 | Intermediate Similarity | NPD9580 | Clinical (unspecified phase) |
0.8218 | Intermediate Similarity | NPD3129 | Phase 3 |
0.8119 | Intermediate Similarity | NPD3128 | Phase 3 |
0.809 | Intermediate Similarity | NPD9556 | Approved |
0.8061 | Intermediate Similarity | NPD5789 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD9560 | Approved |
0.8 | Intermediate Similarity | NPD9561 | Approved |
0.7979 | Intermediate Similarity | NPD755 | Phase 3 |
0.7959 | Intermediate Similarity | NPD502 | Approved |
0.7889 | Intermediate Similarity | NPD9558 | Phase 3 |
0.7826 | Intermediate Similarity | NPD280 | Approved |
0.7826 | Intermediate Similarity | NPD9533 | Phase 2 |
0.7766 | Intermediate Similarity | NPD241 | Discontinued |
0.7742 | Intermediate Similarity | NPD9557 | Clinical (unspecified phase) |
0.766 | Intermediate Similarity | NPD240 | Phase 3 |
0.766 | Intermediate Similarity | NPD170 | Approved |
0.766 | Intermediate Similarity | NPD9562 | Discovery |
0.7653 | Intermediate Similarity | NPD501 | Phase 1 |
0.7593 | Intermediate Similarity | NPD7914 | Suspended |
0.7545 | Intermediate Similarity | NPD3139 | Phase 3 |
0.7527 | Intermediate Similarity | NPD9559 | Phase 1 |
0.7527 | Intermediate Similarity | NPD9529 | Phase 1 |
0.7455 | Intermediate Similarity | NPD3138 | Phase 3 |
0.7447 | Intermediate Similarity | NPD239 | Phase 2 |
0.7447 | Intermediate Similarity | NPD238 | Clinical (unspecified phase) |
0.7423 | Intermediate Similarity | NPD841 | Approved |
0.7374 | Intermediate Similarity | NPD1686 | Approved |
0.7347 | Intermediate Similarity | NPD9565 | Discontinued |
0.7282 | Intermediate Similarity | NPD1454 | Phase 3 |
0.7282 | Intermediate Similarity | NPD1455 | Phase 3 |
0.7273 | Intermediate Similarity | NPD251 | Approved |
0.7041 | Intermediate Similarity | NPD1760 | Approved |
0.6952 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6916 | Remote Similarity | NPD1061 | Clinical (unspecified phase) |
0.6881 | Remote Similarity | NPD1385 | Discontinued |
0.6789 | Remote Similarity | NPD6946 | Approved |
0.67 | Remote Similarity | NPD9603 | Phase 3 |
0.67 | Remote Similarity | NPD9604 | Approved |
0.67 | Remote Similarity | NPD9602 | Phase 3 |
0.6667 | Remote Similarity | NPD500 | Discontinued |
0.6667 | Remote Similarity | NPD762 | Discontinued |
0.6667 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.6581 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6531 | Remote Similarity | NPD9573 | Phase 2 |
0.6442 | Remote Similarity | NPD6943 | Clinical (unspecified phase) |
0.6442 | Remote Similarity | NPD9585 | Discontinued |
0.64 | Remote Similarity | NPD9601 | Approved |
0.6383 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.6337 | Remote Similarity | NPD9555 | Phase 2 |
0.6327 | Remote Similarity | NPD9429 | Discontinued |
0.6292 | Remote Similarity | NPD9503 | Approved |
0.6292 | Remote Similarity | NPD9504 | Approved |
0.6288 | Remote Similarity | NPD7761 | Suspended |
0.625 | Remote Similarity | NPD9407 | Approved |
0.6226 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6216 | Remote Similarity | NPD7651 | Approved |
0.6204 | Remote Similarity | NPD514 | Clinical (unspecified phase) |
0.6154 | Remote Similarity | NPD9554 | Approved |
0.6154 | Remote Similarity | NPD301 | Discontinued |
0.6154 | Remote Similarity | NPD9553 | Approved |
0.6121 | Remote Similarity | NPD284 | Phase 1 |
0.61 | Remote Similarity | NPD9600 | Approved |
0.6095 | Remote Similarity | NPD1331 | Approved |
0.6038 | Remote Similarity | NPD267 | Discontinued |
0.6036 | Remote Similarity | NPD765 | Discontinued |
0.598 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.5946 | Remote Similarity | NPD192 | Phase 2 |
0.5938 | Remote Similarity | NPD9405 | Approved |
0.5882 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.5872 | Remote Similarity | NPD215 | Discontinued |
0.5833 | Remote Similarity | NPD285 | Discontinued |
0.569 | Remote Similarity | NPD2633 | Phase 1 |
0.569 | Remote Similarity | NPD4743 | Phase 2 |
0.5676 | Remote Similarity | NPD6948 | Phase 3 |
0.5667 | Remote Similarity | NPD1805 | Phase 2 |
0.5667 | Remote Similarity | NPD1804 | Phase 2 |
0.5619 | Remote Similarity | NPD205 | Approved |
PubChem CID   | 9872620 |
ChEMBL   | CHEMBL384527 |
ZINC   |
Molecular Weight:   | 561.88 |
ALogP:   | -2.4825 |
MLogP:   | 0.14 |
XLogP:   | -5.145 |
# Rotatable Bonds:   | 16 |
Polar Surface Area:   | 291.84 |
# H-Bond Aceptor:   | 17 |
# H-Bond Donor:   | 7 |
# Rings:   | 2 |
# Heavy Atoms:   | 30 |